FIT Biotech Oy
Company release 16.8.2018 at 4:30 PM EET
FIT Biotech concludes the exploration of secondary listing to First North Sweden -not relevant at the moment
On April 25th 2017, FIT Biotech (“FIT Biotech”, FITBIO: FN Finland) announced that the company explores possibilities for a secondary listing to First North Sweden -market. After conducting additional research on the topic, the company has concluded that a secondary listing is not relevant at this time.
In case the secondary listing becomes relevant in the future, the company will publish a separate company release on the topic.
FIT BIOTECH OY
For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: erkki.pekkarinen@fitbiotech.com
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
www.fitbiotech.com
